Floatz logo

FAZA

Refractory Malignant Neoplasm

University of California, San FranciscoSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

181 Active assets in the Refractory Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Catequentinib
First Affiliated Hospital of Wannan Medical College
Phase 3BB

View all 50 →

Same molecule, other indications

FAZA is also rated in:

Breast NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →
Neuroendocrine TumoursDormant
CC
Indicative ·
41 / 100
View asset →
Renal Cell CarcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →